Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Facebook’s Mark Zuckerberg announces $3bn funding to help cure diseases
The announcement was made at an event in San Francisco, US. The money comes from the Chan Zuckerberg Initiative the couple has started last year for advancing human
The announcement was made at an event in San Francisco, US. The money comes from the Chan Zuckerberg Initiative the couple has started last year for advancing human
Under the five-year, multi-target research partnership, the companies will develop several clinical candidates for the treatment of chronic kidney disease in diabetes patients. Both parties will contribute novel
Tobira is engaged in the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The deal, which is expected to close by the end
In its filing in the US district court of Delaware, Sanofi claims that Merck Sharp & Dohme Corp. violated 10 patents held by it, including ones for its
The phase III DURATION-8 trial showed that Bydureon, taken just once a week in combination with Forxiga once daily significantly reduced blood sugar, compared with the individual medicines
The CHMP adopted a positive opinion recommending approval of Pfizer's Ibrance (palbociclib) in combination with endocrine therapy to treat HR-positive, HER2-negative metastatic breast cancer. Its opinion specifies that
In the Resolve phase 3 trial of 11,856 older adults (60 years of age and older), the vaccine did not meet its efficacy goals, including the primary objective
The drug was studied in patients with type 2 diabetes (T2D) in combination with sitagliptin and metformin. The double-blind, placebo-controlled phase 3 VERTIS SITA2 trial randomized 463 subjects
People who received the two-dose Shingrix vaccine had an 88% lower risk of developing shingles in the fourth year after vaccination, compared with a 91% reduction over the entire
Vitae discovers and develops small molecule drugs for diseases with significant unmet medical needs. The company uses its structure-based drug design platform, Contour, for discovering a portfolio of